{"schemaVersion":"ready-scan.discovery-surface.v1","id":"urn:readyscan:corpus:buyer-question:veristat-q131986594-answer-1a02751483e69f2ab788","key":"buyer_question:veristat-q131986594-answer-1a02751483e69f2ab788","kind":"buyer_question","slug":"veristat-q131986594-answer-1a02751483e69f2ab788","canonicalUrl":"https://readyscan.ai/corpus/buyer-question/veristat-q131986594-answer-1a02751483e69f2ab788","machineUrl":"https://readyscan.ai/discovery/corpus/buyer-question/veristat-q131986594-answer-1a02751483e69f2ab788.json","datePublished":"2026-10-25","dateModified":"2026-10-25","materialFingerprint":"fnv1a64:32f7b50c0ae5102c","membershipFingerprint":"fnv1a64:85a7c038071c850f","relatedEntitySlugs":["veristat-q131986594"],"relatedSurfaceKeys":["buyer_question:veristat-q131986594-answer-3412882f879455f677e8","buyer_question:veristat-q131986594-answer-34458a603e1bff48200e","buyer_question:veristat-q131986594-answer-39b32ed129c8622469be","buyer_question:veristat-q131986594-answer-518eadbfcb69743d223e","buyer_question:veristat-q131986594-answer-5fbc154d4b1ba432fb13","buyer_question:veristat-q131986594-answer-6212fedf973f6b93dd9b","buyer_question:veristat-q131986594-answer-68df9892211ef7060c6a","buyer_question:veristat-q131986594-answer-aa510bdb0ccf031ed5bb","buyer_question:veristat-q131986594-answer-c4405cf9ec71555384b3","buyer_question:veristat-q131986594-answer-cfd6628316e7e985c4b7","buyer_question:veristat-q131986594-answer-fe587a9c2de404de4138","evidence:veristat-q131986594"],"sourceIds":["ready-scan-subjects"],"provenance":[{"snapshotId":"veristat-q131986594-content-20eafb8411341c3d-snapshot","sourceId":"ready-scan-subjects","sourceRecordId":"Q131986594","sourceRevisionId":"Q131986594:content:b79eadc27cef7bcc","sourceContentHash":"fnv1a64:1dce5caf659418af","recordRevisionId":"Q131986594:content:b79eadc27cef7bcc","recordContentHash":"fnv1a64:b2a53c98a2b6b9ea","sourceCanonicalUrl":"https://www.veristat.com/","sourceModifiedAt":"2026-10-25T07:29:48.087Z","observedOn":"2026-10-25","permission":{"basis":"public_information","evidenceUrl":"https://www.veristat.com/"},"attributionUrl":"https://www.veristat.com/"}],"quality":{"method":"same_kind_unique_trigram_floor","minimumUniqueTrigramRatio":0.3,"status":"passed"},"title":"What types of documents do you support?","summary":"Cited source answers across 1 active corpus record.","question":"What types of documents do you support?","answers":[{"entitySlug":"veristat-q131986594","entityName":"Veristat","answer":"“Veristat provides clinical, nonclinical, and CMC regulatory writing support throughout the drug development lifecycle. Our expertise spans protocols, Investigator’s Brochures, Clinical Study Reports, INDs, NDAs, BLAs, MAAs, post-marketing safety reports, and many more.”","sourceUrls":["https://www.veristat.com/regulatory-writing-services"]}]}